An aggressive central giant cell granuloma in a pediatric patient: case report and review of literature

Yiqiao Wang, Andre Le, Dina El Demellawy, Mary Shago, Michael Odell and Stephanie Johnson-Obaseki

Abstract

Background: Central giant cell granulomas are benign tumours of the mandible, presenting in children and young adults. Divided into non- and aggressive subtypes, the aggressive subtype is relatively rare and can occasionally progress rapidly, resulting in significant morbidity.

Case presentation: We present a case of an aggressive central giant cell granuloma (CGCG) in a six year-old female. The lesion originated in the right mandibular ramus and progressed rapidly to involve the condyle. Diagnosis was made using a combination of imaging and pathology. A timely en bloc resection of the hemi-mandible was performed with placement of a reconstructive titanium plate and condylar prosthesis.

Conclusion: Our case demonstrates the importance of considering CGCG in the differential diagnosis of rapidly progressive mandibular lesions in the pediatric population. Prompt diagnosis and management can greatly improve long-term outcomes.

Keywords: Central giant cell granuloma, Mandible, Aggressive, Pediatrics

Background

Central giant cell granuloma (CGCG) is described by the World Health Organization as an intraosseous lesion consisting of cellular fibrous tissue that contains multiple foci of hemorrhage, aggregations of multinucleated giant cells, and some trabeculae of woven bone [1]. These tumours account for 7% of all benign tumours of the mandible, and present with a higher frequency in the mandible than maxilla [2, 3]. There is a slight female predilection, with a peak age incidence range between 10 to 25 years [4, 5]. Aetiology is unknown, however may be related to trauma, inflammatory foci or genetic predisposition [5, 6].

CGCG can be divided into two subtypes, aggressive and non-aggressive [7]. The non-aggressive variant is most common, presenting as a slow-growing, painless lesion with expansion of cortical bone. In contrast, aggressive giant cell granulomas tend to present in younger patients with the following possible features: greater than 5 cm in size, rapid growth, root resorption, tooth displacement leading to malocclusion, cortical bone thinning or perforation, and recurrence after curettage [7–9].

We report an uncommon case of an aggressive CGCG in a 6-year-old female, originating in the right mandibular ramus with extension into the condyle.

Case presentation

A six year-old, previously healthy female initially presented to the dentist with a cavity involving a right mandibular tooth, which was filled. Two days after the appointment, she developed mild facial swelling on the ipsilateral side. Symptoms progressed over the next week, and antibiotics were prescribed for a presumed odontogenic infection. The lesion was refractory to antibiotics, which resulted in her presentation to the Children’s Hospital of Eastern Ontario (CHEO) Emergency Department.

An ultrasound of the face and radiograph of the facial bones was completed (Fig. 1). The radiograph demonstrated a mixed fluid and solid lesion within the right para-mandibular region, measuring 5.8 × 3.4 × 2.9 cm, and with similar consistency to bone (Fig. 1). Similarly,
ultrasound demonstrated a large, expansile, lucent, osseous lesion centered in the right mandibular ramus, and described with benign features. The differential diagnoses at the time included giant cell granuloma, dentigerous cyst, radicular cyst, odontogenic keratocyst, and ameloblastoma. In addition, infection could not be completely excluded.

The child was discharged home, with an urgent magnetic resonance imaging (MRI) and computed tomography (CT) ordered and performed one day after the emergency visit. MRI of the head demonstrated a cystic lesion centered along the ramus of the right mandible, measuring 3.6 × 3.8 × 4.8 cm (Fig. 2). CT of the head demonstrated a lesion involving the right mandibular ramus, angle and posterior body with involvement of the 2nd mandibular molar (Fig. 3). There was no airway or vascular compromise noted on either imaging modality.

A referral was made to Otolaryngology- Head and Neck Surgery. The patient was taken urgently to the operating room (OR) and a trans-oral biopsy of the mandibular mass was performed. Pathology revealed a multicystic lesions. The cysts were devoid of endothelial and epithelial lining and contain areas of hemorrhage. The septa lining the cysts were thick and formed of bland spindle myofibroblasts. Focal hemosiderin deposition and small, unevenly distributed clusters of giant cells were noted. A giant cell granuloma was the favoured diagnosis.

After diagnosis, oral maxillofacial surgery (OMFS) was consulted. The patient was taken again to the OR for enucleation of the tumour, decompression of the right inferior alveolar nerve, and biopsy. The child was to be followed-up by oncology after pathology results returned for consideration of interferon therapy.

Sixteen days later, while awaiting follow-up, the patient re-presented to the CHEO ED with facial swelling, pain and an inability to tolerate feeds. Additionally, she complained of numbness of the right tongue, which she had not experienced previously. Repeat CT demonstrated significant growth of the mass to 6.4 × 4.9 × 4.4 cm (Fig. 4).

Pathology from the second excisional biopsy showed a lesion with multicystic component filled with clotted blood (Figs. 5 and 6). The cysts were devoid of endothelial and epithelial lining and contained areas of hemorrhage. The septa lining the cysts were thick and formed of bland spindle myofibroblasts (Figs. 7 and 8) and enclosed hemosiderin denoting organizing hemorrhage. Scattered small giant cells with a zonal pattern of distribution were noted. Mitotic activity was sparse with 1 mitotic figure/20 high power fields, identified in the spindle cells. Reactive bone formation was noted at the periphery of the lesion (Fig. 8). The findings supported the original diagnosis of a giant cell granuloma. Interphase FISH analysis performed on a paraffin-embedded tissue slide using a dual colour break-apart probe for the USP6 gene locus (17p13.2) was consistent with USP6 gene rearrangement in 93/200 (46.5%) nuclei (Fig. 9).

The patient was seen by Oncology and the consensus was that interferon therapy would not be warranted unless further resection was performed. Due to the significant size and location of the lesion, the adult Head and
Neck Oncology subspecialty service was asked to evaluate the patient. Given the size, patient symptoms, and rapidly growing nature of tumor, the plan was for urgent surgical intervention including a tracheostomy, complete resection of right hemi-mandible and involved buccal mucosa and a complete reconstruction of mandible using a reconstructive titanium plate and condylar prosthesis. The decision to not reconstruct with a bony free tissue flap was made in conjunction with the OMFS team and the adult reconstructive team with the goal to delay the definitive reconstruction and to reassess once the patient was closer to fully grown.

The patient was taken to the OR and surgery proceeded as planned. There were no intraoperative complications. Due to ongoing diagnostic uncertainty, coupled with the malignant clinical behavior of the lesion, a 1.5 cm margin was excised. Postoperatively, the patient was monitored in an intensive care setting. A post-operative day 7 an MRI was obtained, and daily Interferon was started as per oncology at 3,000,000 units subcutaneous daily. The patient was decannulated post-operative day 10 and discharged home after a 13-day admission. Unfortunately she was then admitted on post-operative day 23 with an orocutaneous fistula confirmed via blue dye test. The Interferon at that point was stopped, as there is a known risk of wound dehiscence. She was made NPO and intravenous Cefazolin and Metronidazole were started. She was taken to the operating room for wound debridement and irrigation as well as to facilitate packing of the wound with ribbon gauze. Prior to discharge, packing was changed twice weekly. She was admitted for a total of 32 days and was discharged home on IV Clindamycin as per the Infectious Disease service and feeds via nasogastric tube. She returned to the operating room twice weekly for further packing changes. After 3 further packing changes, the fistula had completely healed and was confirmed to be closed via blue dye test. IV Clindamycin was continued for a total of 6 weeks, and oral Clindamycin then for a further 3 weeks. Further follow-up will include reassessment by the OMFS service and likely exchange to a longer titanium plate, followed by possible definitive reconstruction when she is closer to fully grown.

Discussion

Our case report describes a rare case of an aggressive CGCG originating in the right mandibular ramus with extension into the condyle in a six year-old child. To
our knowledge, only eight other cases of CGCG affecting the mandibular condyle have been presented in literature, and of these, only one occurred in a child [10–17]. Furthermore, only one case required en bloc resection and fibula graft for management [14].

Care should be used to differentiate aggressive and non-aggressive granulomas. In both cases, immunophenotypic and ultrasound findings are similar [18]. Although controversial, in aggressive lesions a higher level of a proliferation marker, Ki-67 may be found [8, 18]. In addition, histomorphometric analysis may show an increased number of giant cells, larger surface area, and greater mitotic activity in the aggressive variant [8]. In our case Ki67 showed a low proliferation index (< 2%) and mitotic figures were rare. Other benign lesions included in the differential diagnosis include: Brown tumors, which are usually multiple lesions and result from increased parathyroid hormone levels, as well as cherubism, which is a congenital disorder causing marked expansion of all 4 quadrants of the jaw. Both of these conditions have similar histopathological features to CGCG [19]. In our case parathyroid hormone levels were not elevated and on imaging there were no other bony or soft tissue lesions identified.

From the pathology prospective our case is interesting as it showed significant cystic areas. CGCG is considered the solid variant of aneurysmal bone cyst, however, aneurysmal bone cystic changes are a finding that can be seen in CGCG. CGCG are usually solid but in a small subset of cases, can show cystic areas with areas identical to aneurysmal bone cyst, as identified in our case. The distinction between CGCG and aneurysmal bone cyst is not feasible particularly on these cases with a dominant and prominent blood-filled cysts. Our case supports the speculation that CGCG is the primary lesion and aneurysmal bone cyst is a secondary change [20]. Thus whether the CGCG is solid or predominately cystic and hemorrhagic simply represents a different stage of the lesion evolution and the difference is likely related to the time of patient’s presentation. The USP6 gene rearrangement identified in our case is a further support to this speculation and the common pathogenesis as USP6 gene rearrangement has been documented to be present in most cases of primary aneurysmal bone cyst [21, 22]. USP6 gene rearrangement has been reported in CGCG previously [21] though our case is the first to report in gnathic location.
Management of CGCG is controversial and differs depending on the aggression, size, and location. Suggested treatment modalities in the literature include: surgery, radiation, interferon, intralesional steroids and tyrosine kinase inhibitors (Imatinib) [7, 23–26]. Of note, although calcitonin has also been suggested as a treatment modality, one randomized controlled trial found no improvement in results compared to placebo [27]. A combination of surgery and adjuvant interferon therapy has shown promise in another study specific for aggressive CGCG, with increased tumor control and decreased operative morbidity [28].

Surgery is the mainstay treatment of the aggressive variant of CGCG, once confirmed via adequate biopsy, typically performed in an operating room setting. Options include: enucleation, curettage and segmental resection. Enucleation and curettage are favourable due to the possible preservation of the cortex of the mandible and inferior alveolar nerve, however these methods are fraught with a recurrence rate of 30–70% in aggressive CGCG. According to one study, segmental resection has the lowest recurrence rate, specifically for lesions that present with pain, rapid growth, facial swelling, and cortical perforation [9, 29]. It is also pertinent to consider airway management for these cases, which may include a temporary tracheostomy as in our scenario.

For the patient presented here, segmental resection was felt to be the most likely treatment to avoid further recurrence and airway compromise. Although a controversial topic, due to the potential for impaired growth in the pediatric population and the possibility of poor function and cosmetic outcomes including malocclusion and asymmetry, this influenced the decision to proceed with titanium prosthesis implant versus vascularized free fibula flap reconstruction in our case [30].

Fig. 7 Medium power light microscopic view of the lesion showing fibrous thick septa with reactive woven bony trabeculae. The later are highlighted by back arrow heads (H&E X400).

Fig. 8 High power light microscopic view of the lesion showing a cystic space and a thick septum formed of myofibroblastic cells. Note the cystic space is devoid of lining (H&E X400).
Conclusions

CGCG should be considered on the differential of any young child with a rapidly growing lesion of the mandible. Prompt diagnosis and management can greatly improve morbidity and long-term outcomes. Further studies are required to determine the optimal management for these lesions, particularly the aggressive variant of CGCG.

Abbreviations

CGCG: Central Giant Cell Granuloma; CHEO: Children’s Hospital of Eastern Ontario; CT: Computed Tomography; MRI: Magnetic Resonance Imaging; OMFS: Oral Maxillofacial Surgery; OR: Operating room

Authors’ contributions

DW compiled clinical data and prepared manuscript. AL was involved in primary patient care, compiled clinical data and revised manuscript. DED was responsible for pathology review and revised manuscript. MS was involved in primary patient care and revised manuscript. SJÖ was involved in primary patient care and revised manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable

Ethics approval and consent to participate

Obtained, see below.

Consent for publication

Institutional (CHEO) consent obtained from legal guardian of patient for publication purposes. Available upon request.

Competing interests

The authors declare that they have no competing interests.

Author details

1Faculty of Medicine, University of Ottawa, Ottawa, Canada. 2Department of Otolaryngology – Head and Neck Surgery, Faculty of Medicine, University of Ottawa, Ottawa, Canada. 3Department of Pathology, Children’s Hospital of Eastern Ontario, Faculty of Medicine, University of Ottawa, Ottawa, Canada. 4Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada. 5Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.

Received: 14 March 2019 Accepted: 9 July 2019 Published online: 18 July 2019

References

1. Barnes L, Everson J, Reichart P. WHO Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC; 2005. p. 234–5.
2. Austin LT Jr, Dahlin DC, Royer RQ. Giant-cell reparative granuloma and related conditions affecting the jawbones. Oral Surg Oral Med Oral Pathol. 1959;12:1285–95.
3. Kaffe I, Ardekian L, Taicher S, Littner MM, Buchner A. Radiologic features of central giant cell granuloma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81(6):720–6.
4. Jaffe HL. Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-osseous) dysplasia of the jawbones. Oral Surg Oral Med Oral Pathol. 1953;6(1):159–75.
5. Eisenbud L, Stern M, Rothberg M, Sachs SA. Central giant cell granuloma of the jaws: experiences in the management of thirty-seven cases. J Oral Maxillofac Surg. 1988;46(5):376–84.
6. Jenkins D, Malotky M, Miremadi R, Dole M. Central Giant cell granuloma of the mandible requiring multiple treatment modalities: a case report. J Oral Maxillofac Surg. 2016;74(8):1596–607.
7. de Lange J, van den Akker HP, van den Berg H. Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(5):562–9.
8. Kruse-Losler B, Diallo R, Gaertner C, Mischke KL, Joos U, Kleinheinz J. Central giant cell granuloma of the jaws: a clinical, radiologic, and histopathologic study of 26 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(3):346–54.
9. Chuong R, Kaban LB, Kozakewich H, Perez-Atayde A. Central giant cell lesions of the jaws: a clinicopathologic study. J Oral Maxillofac Surg. 1986;44(9):708–13.
10. Shensa DR, Nasser S. Central giant cell reparative granuloma of the mandibular condyle. J Oral Surg. 1978;36(8):642–3.
11. Tasanen A, von Konow L. Nordling: central giant-cell lesion in the maxilla in a 8-year old boy. Case Rep Dent. 2017;2017:6545848.
12. Abu-El-Naaj I, Ardekian L, Liberman R, Peled M. Central giant cell granuloma of the mandibular condyle: a case report, literature review, and discussion of treatment. Oral and Maxillofacial Surgery Cases. 2015;1(3):42–6.
13._alzahrawy AM, Beniameen MM, El-Shazly YM, Elzokary MM. Central giant cell granuloma of the mandibular condyle: a case report and review of the literature. Dentomaxillofac Radiol. 2011;40(1):60–4.
14. Munzenmayer J, Tapia P, Zeballos J, Martinez A, Compan A, Ura A, Spencer ML. Central giant cell granuloma of the mandibular condyle: case report. Revista Clínica de Periodoncia, Implantología y Rehabilitación Oral. 2013(62):83–6.
15. Gigliotti J, Alghamdi O, El-Hakim M, Makhoul N. Central giant cell granuloma of the mandibular condyle: a case report, literature review, and discussion of treatment. Oral and Maxillofacial Surgery Cases. 2015;13(1):42–6.
16. Pai D, Kamath AT, Kudva A, Solomon MMC, Kumar S, Sasikumar P. Concomitant central Giant cell granuloma and aneurysmal bone cyst in a young child. Case Rep Dent. 2017;2017:6545848.
17. Della Sala SW, Recla M, Campolongo F, Bortot G, Bauer M, Peterlongo P. Giant cell tumour of the mandibular condyle. Eur Radiol. 1996;6(4):557–60.
18. Janas A, Osica P. Central giant cell granuloma located in the maxilla in a 8-year old boy. Dev Period Med. 2015;19(2):189–92.
19. Bannhofer D. Bone-related lesions of the jaws. Surg Pathol Clin. 2017;10(3):693–704.
20. Struthers PJ, Shear M. Aneurysmal bone cysts of the jaws: Clinicopathological Features and Pathogenesis Int J Oral Surg. 1984;13:85–100.
21. Agaram NP, LeLoarer FV, Zhang L, Hwang S, Athanasian EA, Hameed M, Antonescu CR. USP6 gene rearrangements occur preferentially in giant cell...
reparative granulomas of the hands and feet but not in gnathic location. Hum Pathol. 2014;45(6):1147–52.

22. Oliveira AM, Perez-Atayde AR, Inwards CY, Medeiros F, Derr V, Hsi BL, Gebhardt MC, Rosenberg AE, Fletcher JA. USP6 and CDH11 onco genes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol. 2004;165(5):1773–80.

23. Franco A, Segato AV, Couto SA, Rodrigues Johann AC, Friedlander AH, Couto Souza PH. Spontaneous resolution of a central Giant cell granuloma in a child after an incisional biopsy: a five-year follow-up. J Dent Child (Chic). 2016;83(2):102–5.

24. Carlos R, Sedano HD. Intralosomal corticosteroids as an alternative treatment for central giant cell granuloma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(2):161–6.

25. Nogueira RL, Teixeira RC, Cavalcante RB, Ribeiro RA, Rabenhorst SH. Intralosomal injection of triamcinolone hexacetonide as an alternative treatment for central giant-cell granuloma in 21 cases. Int J Oral Maxillofac Surg. 2010;39(12):1204–10.

26. de Lange J, van Rijin RR, van den Berg H, van den Akker HP. Regression of central giant cell granuloma by a combination of imatinib and interferon: a case report. Br J Oral Maxillofac Surg. 2009;47(1):59–61.

27. de Lange J, van den Akker HP, Veldhuijzen van Zanten GO, Engelshoeve HA, van den Berg H, Klij H. Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study. Int J Oral Maxillofac Surg. 2006;35(9):791–5.

28. Kabani LB, Troulis MJ, Ebb D, August MS, Hornek F, Dodson TB. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg. 2002;60(10):1103–11 discussion 1111-1103.

29. Bataineh AB, Al-Khateeb T, Rawashdeh MA. The surgical treatment of central giant cell granuloma of the mandible. J Oral Maxillofac Surg. 2002;60(7):756–61.

30. Zhang WB, Liang T, Peng X. Mandibular growth after paediatric mandibular reconstruction with the vascularized free fibula flap: a systematic review. Int J Oral Maxillofac Surg. 2016;45(4):440–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.